ArticleJournal of neuroendocrinology2016
Carbetocin is a Functional Selective Gq Agonist That Does Not Promote Oxytocin Receptor Recycling After Inducing β-Arrestin-Independent Internalisation.
Article in Journal of neuroendocrinology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 68 citations in OpenAlex.
- Oxytocin treatment in children with Prader-Willi syndrome: A double-blind, placebo-controlled, crossover study.American journal of medical genetics. Part A · 2017Trial
- Dose-response evaluation of intravenous carbetocin for prevention of postpartum haemorrhage during elective caesarean delivery: A parallel-group randomised controlled trial.Indian journal of anaesthesia · 2026Article
- Article
- The Oxytocin Receptor in Spermatozoa May Originate From Both Spermatogenesis and Epididymal Maturation, and Regulates Capacitation.Andrology · 2026Article
- Stress induces oxytocin-Gαi-dependent remodeling of astrocytes to shape neuronal response in the amygdala.Nature communications · 2025Article
- Fluorescent Peptide Tracers for Simultaneous Oxytocin Receptor Activation and Visualization.Angewandte Chemie (International ed. in English) · 2025Article
- Dual Oxytocin Signals in Striatal Astrocytes.Biomolecules · 2025Article
- Predicting oxytocin binding dynamics in receptor genetic variants through computational modeling.npj women's health · 2025Article
- Environmental enrichment enhances ethanol preference over social reward in male swiss mice: Involvement of oxytocin-dopamine interactions.Neuropharmacology · 2024Article
- Article
- Oxytocin's Regulation of Thermogenesis May Be the Link to Prader-Willi Syndrome.Current issues in molecular biology · 2023Review
- Investigation of metal modulation of oxytocin structure receptor-mediated signaling.RSC chemical biology · 2023Article
- Article
- Oxytocin receptor behavioral effects and cell types in the bed nucleus of the stria terminalis.Hormones and behavior · 2022Article
- Oxytocin accelerates tight junction formation and impairs cellular migration in 3D spheroids: evidence from Gapmer-induced exon skipping.Frontiers in cellular neuroscience · 2022Article
- Alcohol and oxytocin: Scrutinizing the relationship.Neuroscience and biobehavioral reviews · 2021Review
- Convergent neuroendocrine mechanisms of social buffering and stress contagion.Hormones and behavior · 2021Review
- Dynamic regulation of oxytocin neuronal circuits in the sequential processes of prosocial behavior in rodent models.Current research in neurobiology · 2021Review
- Oxytocin-induced anxiogenic behavior in juvenile male rats.Animal cells and systems · 2021Article
- The New Frontier in Oxytocin Physiology: The Oxytonic Contraction.International journal of molecular sciences · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
Carbetocin, a long-acting oxytocin analogue, has been reported to elicit interesting and peculiar behavioural effects. The present study investigated the molecular pharmacology of carbetocin, aiming to better understand the molecular basis of its action in the brain. Using bioluminescence resonance energy transfer biosensors, we characterised the effects of carbetocin on the three human oxytocin/vasopressin receptors expressed in the nervous system: the oxytocin receptor (OXTR) and the vasopressin V1a (V1aR) and V1b (V1bR) receptors. Our results indicate that (i) carbetocin activates the OXTR but not the V1aR and V1bR at which it may act as an antagonist; (ii) carbetocin selectively activates only the OXTR/Gq pathway displaying a strong functional selectivity; (iii) carbetocin is a partial agonist at the OXTR/Gq coupling; (iv) carbetocin promotes OXTR internalisation via a previously unreported β-arrestin-independent pathway; and (v) carbetocin does not induce OXTR recycling to the plasma membrane. Altogether, these molecular pharmacology features identify carbetocin as a substantially different analogue compared to the endogenous oxytocin and, consequently, carbetocin is not expected to mimic oxytocin in the brain. Whether these unique features of carbetocin could be exploited therapeutically remains to be established.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.